Weekly Analysts’ Ratings Updates for DexCom (DXCM)

Several analysts have recently updated their ratings and price targets for DexCom (NASDAQ: DXCM):

• 6/23/2026 – DexCom had its “buy” rating reaffirmed by Benchmark Co..
• 6/23/2026 – DexCom is now covered by Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $86.00 price target on the stock.
• 6/15/2026 – DexCom had its “overweight” rating reaffirmed by Piper Sandler. They now have a $88.00 price target on the stock, up from $75.00.
• 6/10/2026 – DexCom was given a new $95.00 price target by UBS Group AG.
• 6/10/2026 – DexCom had its “buy” rating reaffirmed by TD Cowen. They now have a $95.00 price target on the stock, up from $75.00.
• 6/9/2026 – DexCom was given a new $85.00 price target by Mizuho. They now have an “outperform” rating on the stock.
• 6/8/2026 – DexCom had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $91.00 price target on the stock.
• 6/5/2026 – DexCom was given a new $90.00 price target by Stifel Nicolaus. They now have a “buy” rating on the stock.
• 6/1/2026 – DexCom had its “hold (c-)” rating reaffirmed by Weiss Ratings.
• 5/28/2026 – DexCom had its “buy” rating reaffirmed by Citigroup Inc.. They now have a $84.00 price target on the stock, up from $79.00.
• 5/18/2026 – DexCom was given a new $82.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 5/18/2026 – DexCom had its “underweight” rating reaffirmed by Barclays PLC. They now have a $64.00 price target on the stock, down from $67.00.
• 5/18/2026 – DexCom had its price target lowered by Bank of America Corporation from $100.00 to $80.00. They now have a “buy” rating on the stock.
• 5/15/2026 – DexCom was upgraded by William Blair to “strong-buy”.
• 5/11/2026 – DexCom is now covered by Benchmark Co.. They set a “buy” rating and a $77.00 price target on the stock.
• 5/11/2026 – DexCom was upgraded by Benchmark Co. to “strong-buy”.
• 5/10/2026 – DexCom was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 5/4/2026 – DexCom had its “buy” rating reaffirmed by Citigroup Inc.. They now have a $79.00 price target on the stock, down from $84.00.
• 5/2/2026 – DexCom was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/1/2026 – DexCom was given a new $77.00 price target by Sanford C. Bernstein.
• 5/1/2026 – DexCom was given a new $80.00 price target by Robert W. Baird.
• 5/1/2026 – DexCom was given a new $75.00 price target by Mizuho.
• 5/1/2026 – DexCom was given a new $81.00 price target by Raymond James Financial, Inc..
• 5/1/2026 – DexCom was given a new $100.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 5/1/2026 – DexCom was given a new $67.00 price target by Barclays PLC. They now have an “underweight” rating on the stock.
• 5/1/2026 – DexCom had its price target lowered by TD Cowen from $84.00 to $75.00. They now have a “buy” rating on the stock.

Insider Activity

In related news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the sale, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 46,694 shares of company stock valued at $3,343,977 in the last ninety days. Corporate insiders own 0.28% of the company’s stock.

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.